NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
Clinical Trials
10 trialsNCT03766490 2019-01-30
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT03602027 2018-07-26
Phase I Study of the Combination of Anlotinib With Gefitinib
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT03381430 2017-12-22
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Qilu Pharmaceutical Co., Ltd.
Phase NA Unknown
NCT03157310 2017-05-17
Bone Metastasis on the Survival of Gefitinib Effective Patients
Qilu Hospital of Shandong University
Phase NA Completed
NCT02282267 2017-02-24
Benefit
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT02148380 2016-04-20
Combination of Chemotherapy and Gefitinib as First-line Treatment
Shanghai Chest Hospital
Phase NA Completed
NCT01776684 2013-01-28
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Samsung Medical Center
Phase NA Unknown
NCT00068497 2013-01-14
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase NA Completed
NCT00104728 2012-10-31
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated